Physician profile
Daniel Bui
NPI 1154929107
$6,295.71
in general payments reported to CMS, 2019-2025
17 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.00 · 2021: $148 · 2022: $630 · 2023: $1,616 · 2024: $2,508 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,180 · Entertainment: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,179.78 |
| Entertainment | $313.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,265.04 | 2022-2025 | Total30, Precision 1, Precision7 |
| Bausch & Lomb Americas INC. | $1,040.61 | 2023-2025 | Infuse, Miebo, Vyzulta |
| Visioneering Technologies, INC. | $1,000.00 | 2024 | |
| Sun Pharmaceutical Industries INC. | $559.80 | 2022-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $453.81 | 2021-2025 | Acuvue |
| Optos, INC. | $313.38 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec USA, INC. | $285.01 | 2023-2024 | Cirrus Hd-Oct |
| Glaukos Corporation | $260.15 | 2025 | Photrexa Viscous and Photrexa, Idosetr |
| Dompe US, INC. | $237.59 | 2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $146.17 | 2025 | |
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Abbvie INC. | $126.23 | 2022 | |
| Allergan, INC. | $124.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $121.86 | 2025 | Ultomiris |
| Harrow Eye, LLC | $98.55 | 2025 | Vevye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $94.25 | 2024 | Xdemvy |
| Synergeyes, INC. | $25.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.